Determination of the parathyroid hormone reference interval in patients with different stages of the chronic kidney disease
https://doi.org/10.29235/1814-6023-2021-18-2-186-195
Abstract
Secondary hyperparathyroidism (SHPT) is one of the most clinically significant complications of chronic kidney disease (CKD) due to associated mineral, bone disorders, and metastatic calcification. The indicators of mineral and bone metabolism of 635 patients with different CKD stages and 50 persons of the control group were analyzed using a neural network algorithm and the mathematical technology BootStrаp, which allowed determining the target PTH intervals for each stage in patients with CKD, corresponding to the optimal indicators of mineral density and metabolism bone tissue, in order to improve the survival of this category of patients. It was found that the upper limit of the reference interval of the PTH level in patients with CKD and GFR > 35 ml/min coincides with the general population, in patients with CKD and GFR 15‒35 ml/min it is 185 pg/ml, which is 3 times higher than in the general population, and in patients with CKD and GFR < 15 ml/min it is 500 pg/ml (7.5 times higher than in the general population). In dialysis patients with the PTH level of 500‒1500 pg/ml, it is possible to maintain satisfactory parameters of bone metabolism, and the PTH level of >1500 pg/ml determines the extreme risk of developing severe SHPT complications.
About the Authors
N. V. Karlovich
Republican Center of Medical Rehabilitation and Balneotherapy
Belarus
Belarus
Natalia V. Karlovich ‒ Ph. D. (Med.), Chief Doctor
17, Makayenka Str., 220017, Minsk
O. S. Spiridonova
Belarusian State Medical University
Belarus
Belarus
Olga S. Spiridonova ‒ Junior Researcher
83, Dzerzhinski Ave., 220116, Minsk
E. G. Sazonova
Republican Center of Medical Rehabilitation and Balneotherapy
Belarus
Belarus
Elena G. Sazonova ‒ Endocrinologist
17, Makayenka Str., 220017, Minsk
T. V. Mokhort
Belarusian State Medical University
Belarus
Belarus
Tatiana V. Mokhort ‒ D. Sc. (Med.), Professor, Head of the Department
83, Dzerzhinski Ave., 220116, Minsk
References
1. Horl W. H. The clinical consequences of secondary hyperparathyroidism: focus on clinical outcomes. Nephrology Dialysis Transplantation, 2004, vol. 19, suppl. 5, pp. v2–v8. https://doi.org/10.1093/ndt/gfh1049
2. Moe S. M., Drüeke T., Lameire N., Eknoyan G. Chronic kidney disease – mineral-bone disorder: a new paradigm. Advances in Chronic Kidney Disease, 2007, vol. 14, no. 1, pp. 3–12. https://doi.org/10.1053/j.ackd.2006.10.005
3. Mejía N., Roman-García P., Miar A. B., Tavira B., Cannata-Andía J. B. Chronic kidney disease – mineral and bone disorder: a complex scenario. Nefrologia, 2011, vol. 31, no. 5, pp. 514–519. https://doi.org/10.3265/Nefrologia.pre2011.Jun.10926
4. Miller P. D. Fragility fractures in chronic kidney disease: an opinion-based approach. Cleveland Clinic Journal of Medicine, 2009, vol. 76, no. 12, pp. 715–723. https://doi.org/10.3949/ccjm.76a.08108
5. Tentori F., Blayney M. J., Albert J. M., Gillespie B. W., Kerr P. G., Bommer J. [et al.]. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). American Journal of Kidney Diseases, 2008, vol. 52, no. 3, pp. 519–530. https://doi.org/10.1053/j.ajkd.2008.03.020
6. National Kidney Foundation Dialysis Outcomes Quality Initiative (K/DOQI) guidelines. Available at: https://www.kidney.org/professionals/guidelines (accessed 28.03.2021).
7. Eller-Vainicher C., Falchetti A., Gennari L., Cairoli E., Bertoldo F., Vescini F., Scillitani A., Chiodini I. Diagnosis of endocrine disease: evaluation of bone fragility in endocrine disorders. European Journal of Endocrinology, 2019, vol. 180, no. 6, pp. R213–R232. https://doi.org/10.1530/eje-18-0991
8. Lee J., Vasikaran S. Current recommendations for laboratory testing and use of bone turnover markers in management of osteoporosis. Annals of Laboratory Medicine, 2012, vol. 32, no. 2, pp. 105–112. https://doi.org/10.3343/alm.2012.32.2.105
9. Okuno S., Inaba M., Kitatani K., Ishimura E., Yamakawa T., Nishizawa Y. Serum levels of C-terminal telopeptide of type I collagen: a useful new marker of cortical bone loss in hemodialysis patients. Osteoporosis International, 2005, vol. 16, no. 5, pp. 501–509. https://doi.org/10.1007/s00198-004-1712-4
10. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group: KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD). Kidney International Supplements, 2017, vol. 7, p. e1. https://doi.org/10.1016/j.kisu.2017.10.001
11. ISCD Official Positions 2019 Indications for bone mineral density testing. Available at: https://iscd.org/learn/officialpositions/adult-positions/ (accessed 28.03.2021).
12. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) / G. Eknoyan, N. Lameire, B. L. Kasiske, et al. Kidney International Supplements, 2017, vol. 7, no. 1, pp. 1–59. https://doi.org/10.1016/j.kisu.2017.04.001
Review
For citations:
Karlovich N.V., Spiridonova O.S., Sazonova E.G., Mokhort T.V. Determination of the parathyroid hormone reference interval in patients with different stages of the chronic kidney disease. Proceedings of the National Academy of Sciences of Belarus, Medical series. 2021;18(2):186-195. (In Russ.) https://doi.org/10.29235/1814-6023-2021-18-2-186-195
Views: 560
Email this article 